Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Forodesine - Mundipharma International

X
Drug Profile

Forodesine - Mundipharma International

Alternative Names: BCX-1777; Fodosine; Forodesine hydrochloride; Immucillin-H; Mundesine

Latest Information Update: 14 Apr 2021

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Albert Einstein College of Medicine; Industrial Research Limited
  • Developer BioCryst Pharmaceuticals; Mundipharma International
  • Class Antineoplastics; Antipsoriatics; Purine nucleosides; Pyrimidinones; Small molecules
  • Mechanism of Action Immunosuppressants; Purine nucleoside phosphorylase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Adult T-cell leukaemia-lymphoma; Chronic lymphocytic leukaemia; Cutaneous T-cell lymphoma; Peripheral T-cell lymphoma; Precursor cell lymphoblastic leukaemia-lymphoma; Leukaemia; T-cell prolymphocytic leukaemia; Hairy cell leukaemia
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Peripheral T-cell lymphoma
  • No development reported Chronic lymphocytic leukaemia
  • Discontinued Cutaneous T-cell lymphoma; Haematological malignancies

Most Recent Events

  • 14 Apr 2021 Discontinued - Phase-I for Haematological malignancies (Recurrent, Second-line therapy or greater) in Japan (PO) (Mundipharma pipeline, April 2021)
  • 14 Apr 2021 Discontinued - Phase-II for Chronic lymphocytic leukaemia (Second-line therapy or greater) in USA (PO) (Mundipharma pipeline, April 2021)
  • 14 Apr 2021 Discontinued - Phase-II for Cutaneous T-cell lymphoma (Second-line therapy or greater) in USA, Australia, Switzerland, Austria, Finland, Italy, France, Germany, Spain and United Kingdom (PO) (Mundipharma pipeline, April 2021)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top